Name
|
Sequence
|
Quantity
|
Weight
|
Price
|
Angiotensin I Converting Enzyme Inhibitor
|
RPGFSPFR
|
≥95.0%
|
1mg
|
¥120
|
Angiotensin I Converting Enzyme Inhibitor
|
RPGFSPFR
|
≥95.0%
|
5mg
|
¥360
|
Angiotensin Converting Enzyme Inhibitor
|
Glp-WPRPQIPP
|
≥95.0%
|
1mg
|
¥135
|
Angiotensin Converting Enzyme Inhibitor
|
Glp-WPRPQIPP
|
≥95.0%
|
5mg
|
¥405
|
Acetalin-3
|
Ac-RFMWMK-NH2
|
≥95.0%
|
1mg
|
¥110
|
Acetalin-3
|
Ac-RFMWMK-NH2
|
≥95.0%
|
5mg
|
¥330
|
Acetalin-2
|
Ac-RFMWMR-NH2
|
≥95.0%
|
1mg
|
¥110
|
Acetalin-2
|
Ac-RFMWMR-NH2
|
≥95.0%
|
5mg
|
¥330
|
Acetalin-1
|
Ac-RFMWMT-NH2
|
≥95.0%
|
1mg
|
¥110
|
Acetalin-1
|
Ac-RFMWMT-NH2
|
≥95.0%
|
5mg
|
¥330
|
ACTH (18-39), human
|
RPVKVYPNGAEDESAEAFPLEF
|
≥95.0%
|
1mg
|
¥330
|
ACTH (18-39), human
|
RPVKVYPNGAEDESAEAFPLEF
|
≥95.0%
|
5mg
|
¥990
|
ACTH (6-24), human
|
HFRWGKPVGKKRRPVKVYP
|
≥95.0%
|
1mg
|
¥285
|
ACTH (6-24), human
|
HFRWGKPVGKKRRPVKVYP
|
≥95.0%
|
5mg
|
¥285
|
ACTH (4-10), human
|
MEHFRWG
|
≥95.0%
|
1mg
|
¥105
|
ACTH (4-10), human
|
MEHFRWG
|
≥95.0%
|
5mg
|
¥315
|
ACTH (4-11), human
|
MEHFRWGK
|
≥95.0%
|
1mg
|
¥120
|
ACTH (4-11), human
|
MEHFRWGK
|
≥95.0%
|
5mg
|
¥360
|
ACTH (1-10), human
|
SYSMEHFRWG
|
≥95.0%
|
1mg
|
¥150
|
ACTH (1-10), human
|
SYSMEHFRWG
|
≥95.0%
|
5mg
|
¥450
|
ACTH (1-13), human
|
SYSMEHFRWGKPV
|
≥95.0%
|
1mg
|
¥165
|
ACTH (1-13), human
|
SYSMEHFRWGKPV
|
≥95.0%
|
5mg
|
¥495
|
ACTH (1-16), human
|
SYSMEHFRWGKPVGKK
|
≥95.0%
|
1mg
|
¥240
|
ACTH (1-16), human
|
SYSMEHFRWGKPVGKK
|
≥95.0%
|
5mg
|
¥720
|
ACTH (1-17), human
|
SYSMEHFRWGKPVGKKR
|
≥95.0%
|
1mg
|
¥255
|
ACTH (1-17), human
|
SYSMEHFRWGKPVGKKR
|
≥95.0%
|
5mg
|
¥765
|
ACTH (1-24), human
|
SYSMEHFRWGKPVGKKRRPVKVYP
|
≥95.0%
|
1mg
|
¥360
|
ACTH (1-24), human
|
SYSMEHFRWGKPVGKKRRPVKVYP
|
≥95.0%
|
5mg
|
¥1,080
|
ACTH (1-39), human
|
SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF
|
≥95.0%
|
1mg
|
¥624
|
ACTH (1-39), human
|
SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF
|
≥95.0%
|
5mg
|
¥1,872
|
ACTH (1-39), rat
|
SYSMEHFRWGKPVGKKRRPVKVYPNVAENESAEAFPLEF
|
≥95.0%
|
1mg
|
¥624
|
ACTH (1-39), rat
|
SYSMEHFRWGKPVGKKRRPVKVYPNVAENESAEAFPLEF
|
≥95.0%
|
5mg
|
¥1,872
|
N-Acetyl, ACTH (1-17), human
|
Ac-SYSMEHFRWGKPVGKKR
|
≥95.0%
|
1mg
|
¥255
|
N-Acetyl, ACTH (1-17), human
|
Ac-SYSMEHFRWGKPVGKKR
|
≥95.0%
|
5mg
|
¥765
|
Pro-Adrenomedullin (N-20), rat
|
ARLDTSSQFRKKWNKWALSR-NH2
|
≥95.0%
|
1mg
|
¥312
|
Pro-Adrenomedullin (N-20), rat
|
ARLDTSSQFRKKWNKWALSR-NH2
|
≥95.0%
|
5mg
|
¥936
|
Pro-Adrenomedullin (N-20), porcine
|
ARLDVAAEFRKKWNKWALSR-NH2
|
≥95.0%
|
1mg
|
¥312
|
Pro-Adrenomedullin (N-20), porcine
|
ARLDVAAEFRKKWNKWALSR-NH2
|
≥95.0%
|
5mg
|
¥936
|
Pro-Adrenomedullin (N-20), human
|
ARLDVASEFRKKWNKWALSR-NH2
|
≥95.0%
|
1mg
|
¥312
|
Pro-Adrenomedullin (N-20), human
|
ARLDVASEFRKKWNKWALSR-NH2
|
≥95.0%
|
5mg
|
¥936
|
Adrenomedullin (22-52), human
|
TVQKLAHQIYQFTDKDKDNVAPRSKISPQGY-NH2
|
≥95.0%
|
1mg
|
¥527
|
Adrenomedullin (22-52), human
|
TVQKLAHQIYQFTDKDKDNVAPRSKISPQGY-NH2
|
≥95.0%
|
5mg
|
¥1,581
|
Adrenomedullin (1-12), human
|
YRQSMNNFQGLR
|
≥95.0%
|
1mg
|
¥120
|
Adrenomedullin (1-12), human
|
YRQSMNNFQGLR
|
≥95.0%
|
5mg
|
¥360
|
Allatostatins/Allatostatin I
|
APSGAQRLYGFGL-NH2
|
≥95.0%
|
1mg
|
¥205
|
Allatostatins/Allatostatin I
|
APSGAQRLYGFGL-NH2
|
≥95.0%
|
5mg
|
¥615
|
Allatostatin IV
|
DRLYSFGL-NH2
|
≥95.0%
|
1mg
|
¥130
|
Allatostatin IV
|
DRLYSFGL-NH2
|
≥95.0%
|
5mg
|
¥390
|
Allatostatin II
|
GDGRLYAFGL-NH2
|
≥95.0%
|
1mg
|
¥160
|
Allatostatin II
|
GDGRLYAFGL-NH2
|
≥95.0%
|
5mg
|
¥480
|
Allatostatin III
|
GGSLYSFGL-NH2
|
≥95.0%
|
1mg
|
¥145
|
Allatostatin III
|
GGSLYSFGL-NH2
|
≥95.0%
|
5mg
|
¥435
|
Magainin Spacer Peptide
|
DAEAVGPEAFADQDLDEREVR
|
≥95.0%
|
1mg
|
¥316
|
Magainin Spacer Peptide
|
DAEAVGPEAFADQDLDEREVR
|
≥95.0%
|
5mg
|
¥948
|
Histatin 5
|
DSHAKRHHGYKRKFHEKHHSHRGY
|
≥95.0%
|
1mg
|
¥360
|
Histatin 5
|
DSHAKRHHGYKRKFHEKHHSHRGY
|
≥95.0%
|
5mg
|
¥1,080
|
Indolicidin
|
ILPWKWPWWPWRR-NH2
|
≥95.0%
|
1mg
|
¥205
|
Indolicidin
|
ILPWKWPWWPWRR-NH2
|
≥95.0%
|
5mg
|
¥615
|
Angiotensin III, human
|
RVYIHPF
|
≥95.0%
|
1mg
|
¥105
|
Angiotensin III, human
|
RVYIHPF
|
≥95.0%
|
5mg
|
¥315
|
Angiotensin II, human
|
DRVYIHPF
|
≥95.0%
|
1mg
|
¥120
|
Angiotensin II, human
|
DRVYIHPF
|
≥95.0%
|
5mg
|
¥360
|
Angiotensin I, human
|
DRVYIHPFHL
|
≥95.0%
|
1mg
|
¥150
|
Angiotensin I, human
|
DRVYIHPFHL
|
≥95.0%
|
5mg
|
¥450
|
CD36 Peptide P (139-155)
|
CNLAVAAASHIYQNQFVQ
|
≥95.0%
|
1mg
|
¥255
|
CD36 Peptide P (139-155)
|
CNLAVAAASHIYQNQFVQ
|
≥95.0%
|
5mg
|
¥765
|
Angiotensin II Antipeptide
|
EGVYVHPV
|
≥95.0%
|
1mg
|
¥120
|
Angiotensin II Antipeptide
|
EGVYVHPV
|
≥95.0%
|
5mg
|
¥360
|
Angiotensin II (5-8), human
|
IHPF
|
≥95.0%
|
1mg
|
¥60
|
Angiotensin II (5-8), human
|
IHPF
|
≥95.0%
|
5mg
|
¥180
|
CD36 Peptide P (93-110)
|
YRVRFLAKENVTQDAEDNC
|
≥95.0%
|
1mg
|
¥270
|
CD36 Peptide P (93-110)
|
YRVRFLAKENVTQDAEDNC
|
≥95.0%
|
5mg
|
¥810
|
Biotinyl-Angiotensin I
|
Biotin-DRVYIHPFHL
|
≥95.0%
|
1mg
|
¥175
|
Biotinyl-Angiotensin I
|
Biotin-DRVYIHPFHL
|
≥95.0%
|
5mg
|
¥525
|
Fibrinogen-Binding Peptide
|
EHIPA
|
≥95.0%
|
1mg
|
¥75
|
Fibrinogen-Binding Peptide
|
EHIPA
|
≥95.0%
|
5mg
|
¥225
|
Anti-Inflammatory Peptide 1
|
MQMKKVLDS
|
≥95.0%
|
1mg
|
¥135
|
Anti-Inflammatory Peptide 1
|
MQMKKVLDS
|
≥95.0%
|
5mg
|
¥405
|
Cecropin P1, porcine
|
SWLSKTAKKLENSAKKRISEGIAIAIQGGPR
|
≥95.0%
|
1mg
|
¥480
|
Cecropin P1, porcine
|
SWLSKTAKKLENSAKKRISEGIAIAIQGGPR
|
≥95.0%
|
5mg
|
¥1,440
|
Cecropin A-melittin hybrid peptide [CA(1-7)M(2-9)NH2]
|
KWKLFKKIGAVLKVL-NH2
|
≥95.0%
|
1mg
|
¥235
|
Cecropin A-melittin hybrid peptide [CA(1-7)M(2-9)NH2]
|
KWKLFKKIGAVLKVL-NH2
|
≥95.0%
|
5mg
|
¥705
|
Magainin 2
|
GIGKFLHSAKKFGKAFVGEIMNS
|
≥95.0%
|
1mg
|
¥368
|
Magainin 2
|
GIGKFLHSAKKFGKAFVGEIMNS
|
≥95.0%
|
5mg
|
¥1,104
|
Magainin I
|
GIGKFLHSAGKFGKAFVGEIMKS
|
≥95.0%
|
1mg
|
¥368
|
Magainin I
|
GIGKFLHSAGKFGKAFVGEIMKS
|
≥95.0%
|
5mg
|
¥1,104
|
Lactoferricin, bovine, (BLFC)
|
RRWQWRMKKLG
|
≥95.0%
|
1mg
|
¥165
|
Lactoferricin, bovine, (BLFC)
|
RRWQWRMKKLG
|
≥95.0%
|
5mg
|
¥495
|
Apelin-13, human, bovine
|
QRPRLSHKGPMPF
|
≥95.0%
|
1mg
|
¥195
|
Apelin-13, human, bovine
|
QRPRLSHKGPMPF
|
≥95.0%
|
5mg
|
¥585
|
(Glp1)-Apelin-13, human, bovine
|
Glp-RPRLSHKGPMPF
|
≥95.0%
|
1mg
|
¥220
|
(Glp1)-Apelin-13, human, bovine
|
Glp-RPRLSHKGPMPF
|
≥95.0%
|
5mg
|
¥660
|
α-Bag Cell Peptide (1-7)
|
APRLRFY
|
≥95.0%
|
1mg
|
¥105
|
α-Bag Cell Peptide (1-7)
|
APRLRFY
|
≥95.0%
|
5mg
|
¥315
|
α-Bag Cell Peptide (1-8)
|
APRLRFYS
|
≥95.0%
|
1mg
|
¥120
|
α-Bag Cell Peptide (1-8)
|
APRLRFYS
|
≥95.0%
|
5mg
|
¥360
|
α-Bag Cell Peptide (1-9)
|
APRLRFYSL
|
≥95.0%
|
1mg
|
¥135
|
α-Bag Cell Peptide (1-9)
|
APRLRFYSL
|
≥95.0%
|
5mg
|
¥405
|
γ-Bag Cell Factor
|
RLRFD
|
≥95.0%
|
1mg
|
¥75
|
γ-Bag Cell Factor
|
RLRFD
|
≥95.0%
|
5mg
|
¥225
|
β-Bag Cell Factor
|
RLRFH
|
≥95.0%
|
1mg
|
¥75
|
β-Bag Cell Factor
|
RLRFH
|
≥95.0%
|
5mg
|
¥225
|
β-Amyloid (1-14)
|
DAEFRHDSGYEVHH
|
≥95.0%
|
1mg
|
¥280
|
β-Amyloid (1-14)
|
DAEFRHDSGYEVHH
|
≥95.0%
|
5mg
|
¥840
|
β-Amyloid (1-13)
|
DAEFRHDSGYEVH
|
≥95.0%
|
1mg
|
¥260
|
β-Amyloid (1-13)
|
DAEFRHDSGYEVH
|
≥95.0%
|
5mg
|
¥780
|
β-Amyloid (1-12)
|
DAEFRHDSGYEV
|
≥95.0%
|
1mg
|
¥240
|
β-Amyloid (1-12)
|
DAEFRHDSGYEV
|
≥95.0%
|
5mg
|
¥720
|
β-Amyloid (1-11)
|
DAEFRHDSGYE
|
≥95.0%
|
1mg
|
¥220
|
β-Amyloid (1-11)
|
DAEFRHDSGYE
|
≥95.0%
|
5mg
|
¥660
|
β-Amyloid (1-10)
|
DAEFRHDSGY
|
≥95.0%
|
1mg
|
¥200
|
β-Amyloid (1-10)
|
DAEFRHDSGY
|
≥95.0%
|
5mg
|
¥600
|
β-Amyloid (1-9)
|
DAEFRHDSG
|
≥95.0%
|
1mg
|
¥180
|
β-Amyloid (1-9)
|
DAEFRHDSG
|
≥95.0%
|
5mg
|
¥540
|
β-Amyloid (1-20)
|
DAEFRHDSGYEVHHQKLVFF
|
≥95.0%
|
1mg
|
¥400
|
β-Amyloid (1-20)
|
DAEFRHDSGYEVHHQKLVFF
|
≥95.0%
|
5mg
|
¥1,200
|
β-Amyloid (1-18)
|
DAEFRHDSGYEVHHQKLV
|
≥95.0%
|
1mg
|
¥360
|
β-Amyloid (1-18)
|
DAEFRHDSGYEVHHQKLV
|
≥95.0%
|
5mg
|
¥1,080
|
Bombesin
|
Glp-QRLGNQWAVGHLM-NH2
|
≥95.0%
|
1mg
|
¥254
|
Bombesin
|
Glp-QRLGNQWAVGHLM-NH2
|
≥95.0%
|
5mg
|
¥762
|
Osteocalcin (37-49), human
|
GFQEAYRRFYGPV
|
≥95.0%
|
1mg
|
¥195
|
Osteocalcin (37-49), human
|
GFQEAYRRFYGPV
|
≥95.0%
|
5mg
|
¥585
|
Myelopeptide-2 (MP-2)
|
LVVYPW
|
≥95.0%
|
1mg
|
¥90
|
Myelopeptide-2 (MP-2)
|
LVVYPW
|
≥95.0%
|
5mg
|
¥270
|
Bone Gla Protein (45-49)
|
FYGPV
|
≥95.0%
|
1mg
|
¥75
|
Bone Gla Protein (45-49)
|
FYGPV
|
≥95.0%
|
5mg
|
¥225
|
[Tyr38, Phe42,46] Bone Gla Protein
|
YQEAFRRFFGPV
|
≥95.0%
|
1mg
|
¥180
|
[Tyr38, Phe42,46] Bone Gla Protein
|
YQEAFRRFFGPV
|
≥95.0%
|
5mg
|
¥540
|
[Tyr0] Bradykinin
|
YRPPGFSPFR
|
≥95.0%
|
1mg
|
¥150
|
[Tyr0] Bradykinin
|
YRPPGFSPFR
|
≥95.0%
|
5mg
|
¥450
|
Bradykinin
|
RPPGFSPFR
|
≥95.0%
|
1mg
|
¥135
|
Bradykinin
|
RPPGFSPFR
|
≥95.0%
|
5mg
|
¥405
|
[Thi5,8,DPhe7] Bradykinin
|
RPPG-Thi-S-DPhe-Thi-R
|
≥95.0%
|
1mg
|
¥210
|
[Thi5,8,DPhe7] Bradykinin
|
RPPG-Thi-S-DPhe-Thi-R
|
≥95.0%
|
5mg
|
¥630
|
Fam-Bradykinin
|
5FAM-RPPGFSPFR
|
≥95.0%
|
1mg
|
¥235
|
Fam-Bradykinin
|
5FAM-RPPGFSPFR
|
≥95.0%
|
5mg
|
¥705
|
CART (55-76), rat
|
IPIYEKKYGQVPMCDAGEQCAV(Cys14&Cys20 bridge)
|
≥95.0%
|
1mg
|
¥352
|
CART (55-76), rat
|
IPIYEKKYGQVPMCDAGEQCAV(Cys14&Cys20 bridge)
|
≥95.0%
|
5mg
|
¥1,056
|
Cholecystokinin, CCK Tetrapeptide (30-33)
|
WMDF-NH2
|
≥95.0%
|
1mg
|
¥70
|
Cholecystokinin, CCK Tetrapeptide (30-33)
|
WMDF-NH2
|
≥95.0%
|
5mg
|
¥210
|
Cholecystokinin, CCK Octapeptide (26-33), Non-Sulfated form
|
DYMGWMDF-NH2
|
≥95.0%
|
1mg
|
¥130
|
Cholecystokinin, CCK Octapeptide (26-33), Non-Sulfated form
|
DYMGWMDF-NH2
|
≥95.0%
|
5mg
|
¥390
|
Katacalcin
|
DMSSDLERDHRPHVSMPQNAN
|
≥95.0%
|
1mg
|
¥315
|
Katacalcin
|
DMSSDLERDHRPHVSMPQNAN
|
≥95.0%
|
5mg
|
¥945
|
Calcitonin, rat
|
CGNLSTCMLGTYTQDLNKFHTFPQTSIGVGAP-NH2 (C1&C7 bridge)
|
≥95.0%
|
1mg
|
¥664
|
Calcitonin, rat
|
CGNLSTCMLGTYTQDLNKFHTFPQTSIGVGAP-NH2 (C1&C7 bridge)
|
≥95.0%
|
5mg
|
¥1,992
|
Calcitonin, human
|
CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP-NH2 (C1&C7 bridge)
|
≥95.0%
|
1mg
|
¥664
|
Calcitonin, human
|
CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP-NH2 (C1&C7 bridge)
|
≥95.0%
|
5mg
|
¥1,992
|
Human CMV pp65 (495-503)
|
NLVPMVATV
|
≥95.0%
|
1mg
|
¥135
|
Human CMV pp65 (495-503)
|
NLVPMVATV
|
≥95.0%
|
5mg
|
¥405
|
a-Helical Corticotropin Releasing Factor (12-41)
|
FHLLREMLEMAKAEQEAEQAALNRLLLEEA-NH2
|
≥95.0%
|
1mg
|
¥492
|
a-Helical Corticotropin Releasing Factor (12-41)
|
FHLLREMLEMAKAEQEAEQAALNRLLLEEA-NH2
|
≥95.0%
|
5mg
|
¥1,476
|
Cortistatin 29 (1-13)
|
Glp-ERPPLQQPPHRD
|
≥95.0%
|
1mg
|
¥195
|
Cortistatin 29 (1-13)
|
Glp-ERPPLQQPPHRD
|
≥95.0%
|
5mg
|
¥585
|
Proinsulin C-Peptide (55-89), ?human
|
RREAEDLQVGQVELGGGPGAGSLQPLALEGSLQKR
|
≥95.0%
|
1mg
|
¥630
|
Proinsulin C-Peptide (55-89), ?human
|
RREAEDLQVGQVELGGGPGAGSLQPLALEGSLQKR
|
≥95.0%
|
5mg
|
¥1,890
|
SMCY (950-960) (human)
|
SPSVDKARAEL
|
≥95.0%
|
1mg
|
¥165
|
SMCY (950-960) (human)
|
SPSVDKARAEL
|
≥95.0%
|
5mg
|
¥495
|
Delta-Sleep Inducing Peptide
|
WAGGDASGE
|
≥95.0%
|
1mg
|
¥135
|
Delta-Sleep Inducing Peptide
|
WAGGDASGE
|
≥95.0%
|
5mg
|
¥405
|
DISP
|
WAGGDASGE
|
≥98.0%
|
1mg
|
¥162
|
DISP
|
WAGGDASGE
|
≥98.0%
|
5mg
|
¥486
|
Dynorphin A (2-17), porcine
|
GGFLRRIRPKLKWDNQ
|
≥95.0%
|
1mg
|
¥240
|
Dynorphin A (2-17), porcine
|
GGFLRRIRPKLKWDNQ
|
≥95.0%
|
5mg
|
¥720
|
Dynorphin (2-17), amide, porcine
|
GGFLRRIRPKLKWDNQ-NH2
|
≥95.0%
|
1mg
|
¥250
|
Dynorphin (2-17), amide, porcine
|
GGFLRRIRPKLKWDNQ-NH2
|
≥95.0%
|
5mg
|
¥750
|
Dynorphin B (1-9)
|
YGGFLRRQF
|
≥95.0%
|
1mg
|
¥135
|
Dynorphin B (1-9)
|
YGGFLRRQF
|
≥95.0%
|
5mg
|
¥405
|
Dynorphin A (1-13), porcine
|
YGGFLRRIRPKLK
|
≥95.0%
|
1mg
|
¥195
|
Dynorphin A (1-13), porcine
|
YGGFLRRIRPKLK
|
≥95.0%
|
5mg
|
¥585
|
Dynorphin A (1-13), amide, porcine
|
YGGFLRRIRPKLK-NH2
|
≥95.0%
|
1mg
|
¥205
|
Dynorphin A (1-13), amide, porcine
|
YGGFLRRIRPKLK-NH2
|
≥95.0%
|
5mg
|
¥615
|
Dynorphin A (1-17)
|
YGGFLRRIRPKLKWDNQ
|
≥95.0%
|
1mg
|
¥255
|
Dynorphin A (1-17)
|
YGGFLRRIRPKLKWDNQ
|
≥95.0%
|
5mg
|
¥765
|
Dynorphin A amide, porcine
|
YGGFLRRIRPKLKWDNQ-NH2
|
≥95.0%
|
1mg
|
¥265
|
Dynorphin A amide, porcine
|
YGGFLRRIRPKLKWDNQ-NH2
|
≥95.0%
|
5mg
|
¥795
|
IRL-1720
|
Ac-DKEAVYFAHLDIIW
|
≥95.0%
|
1mg
|
¥225
|
IRL-1720
|
Ac-DKEAVYFAHLDIIW
|
≥95.0%
|
5mg
|
¥675
|
Met-Enkephalin
|
YGGFM
|
≥95.0%
|
1mg
|
¥75
|
Met-Enkephalin
|
YGGFM
|
≥95.0%
|
5mg
|
¥225
|
EXENDIN (9-39)
|
DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2
|
≥95.0%
|
1mg
|
¥527
|
EXENDIN (9-39)
|
DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2
|
≥95.0%
|
5mg
|
¥1,581
|
Exendin-4
|
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2
|
≥95.0%
|
1mg
|
¥720
|
Exendin-4
|
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2
|
≥95.0%
|
5mg
|
¥2,160
|
Fibronectin CS1 Peptide
|
EILDVPST
|
≥95.0%
|
1mg
|
¥120
|
Fibronectin CS1 Peptide
|
EILDVPST
|
≥95.0%
|
5mg
|
¥360
|
G-R-G-D-S-P
|
GRGDSP
|
≥95.0%
|
1mg
|
¥90
|
G-R-G-D-S-P
|
GRGDSP
|
≥95.0%
|
5mg
|
¥270
|
Collagen Binding Fragment
|
CQDSETRTFY
|
≥95.0%
|
1mg
|
¥150
|
Collagen Binding Fragment
|
CQDSETRTFY
|
≥95.0%
|
5mg
|
¥450
|
[Glu1] Fibrinopeptide B, human
|
EGVNDNEEGFFSAR
|
≥95.0%
|
1mg
|
¥210
|
[Glu1] Fibrinopeptide B, human
|
EGVNDNEEGFFSAR
|
≥95.0%
|
5mg
|
¥630
|
[Tyr0] Fibrinopeptide A, human
|
YADSGEGDFLAEGGGVR
|
≥95.0%
|
1mg
|
¥255
|
[Tyr0] Fibrinopeptide A, human
|
YADSGEGDFLAEGGGVR
|
≥95.0%
|
5mg
|
¥765
|
FMRF-amide
|
FMRF-NH2
|
≥95.0%
|
1mg
|
¥70
|
FMRF-amide
|
FMRF-NH2
|
≥95.0%
|
5mg
|
¥210
|
Galantide
|
GWTLNSAGYLLGPQQFFGLM-NH2
|
≥95.0%
|
1mg
|
¥330
|
Galantide
|
GWTLNSAGYLLGPQQFFGLM-NH2
|
≥95.0%
|
5mg
|
¥990
|
Galanin, rat
|
GWTLNSAGYLLGPHAIDNHRSFSDKHGLT-NH2
|
≥95.0%
|
1mg
|
¥474
|
Galanin, rat
|
GWTLNSAGYLLGPHAIDNHRSFSDKHGLT-NH2
|
≥95.0%
|
5mg
|
¥1,422
|
Galanin, human
|
GWTLNSAGYLLGPHAVGNHRSFSDKNGLTS
|
≥95.0%
|
1mg
|
¥510
|
Galanin, human
|
GWTLNSAGYLLGPHAVGNHRSFSDKNGLTS
|
≥95.0%
|
5mg
|
¥1,530
|
M40
|
GWTLNSAGYLLGPPPALALA-NH2
|
≥95.0%
|
1mg
|
¥310
|
M40
|
GWTLNSAGYLLGPPPALALA-NH2
|
≥95.0%
|
5mg
|
¥930
|
M35
|
GWTLNSAGYLLGPPPGFSPFR-NH2
|
≥95.0%
|
1mg
|
¥326
|
M35
|
GWTLNSAGYLLGPPPGFSPFR-NH2
|
≥95.0%
|
5mg
|
¥978
|
GHRF (1-29), amide, rat
|
HADAIFTSSYRRILGQLYARKLLHEIMNR-NH2
|
≥95.0%
|
1mg
|
¥474
|
GHRF (1-29), amide, rat
|
HADAIFTSSYRRILGQLYARKLLHEIMNR-NH2
|
≥95.0%
|
5mg
|
¥1,422
|
GHRF (1-29), amide, human
|
YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH2
|
≥95.0%
|
1mg
|
¥474
|
GHRF (1-29), amide, human
|
YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH2
|
≥95.0%
|
5mg
|
¥1,422
|
GLP-1 (7-37) (human, bovine, guinea pig, mouse, rat)
|
HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG
|
≥95.0%
|
1mg
|
¥527
|
GLP-1 (7-37) (human, bovine, guinea pig, mouse, rat)
|
HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG
|
≥95.0%
|
5mg
|
¥1,581
|
GLP-1 (7-36), amide, chicken, common turkey
|
HAEGTYTSDITSYLEGQAAKEFIAWLVNGR-NH2
|
≥95.0%
|
1mg
|
¥510
|
GLP-1 (7-36), amide, chicken, common turkey
|
HAEGTYTSDITSYLEGQAAKEFIAWLVNGR-NH2
|
≥95.0%
|
5mg
|
¥1,530
|
GLP-1/Glucagon-Like Peptide, human
|
HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG
|
≥95.0%
|
1mg
|
¥660
|
GLP-1/Glucagon-Like Peptide, human
|
HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG
|
≥95.0%
|
5mg
|
¥1,980
|
GLP-1/Glucagon-Like Peptide, amide, human
|
HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH2
|
≥95.0%
|
1mg
|
¥680
|
GLP-1/Glucagon-Like Peptide, amide, human
|
HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH2
|
≥95.0%
|
5mg
|
¥2,040
|
[Des-His1,Glu9] Glucagon, amide
|
SQGTFTSEYSKYLDSRRAQDFVQWLMNT-NH2
|
≥95.0%
|
1mg
|
¥680
|
[Des-His1,Glu9] Glucagon, amide
|
SQGTFTSEYSKYLDSRRAQDFVQWLMNT-NH2
|
≥95.0%
|
5mg
|
¥2,040
|
GLP-2, human
|
HADGSFSDEMNTILDNLAARDFINWLIQTKITD
|
≥95.0%
|
1mg
|
¥561
|
GLP-2, human
|
HADGSFSDEMNTILDNLAARDFINWLIQTKITD
|
≥95.0%
|
5mg
|
¥1,683
|
Glucagon-Like Peptide II, human
|
HADGSFSDEMNTILDNLAARDFINWLIQTKITDR
|
≥95.0%
|
1mg
|
¥578
|
Glucagon-Like Peptide II, human
|
HADGSFSDEMNTILDNLAARDFINWLIQTKITDR
|
≥95.0%
|
5mg
|
¥1,734
|
Glucagon-Like Peptide II, rat
|
HADGSFSDEMNTILDNLATRDFINWLIQTKITD
|
≥95.0%
|
1mg
|
¥561
|
Glucagon-Like Peptide II, rat
|
HADGSFSDEMNTILDNLATRDFINWLIQTKITD
|
≥95.0%
|
5mg
|
¥1,683
|
Glucagon, human
|
HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
|
≥95.0%
|
1mg
|
¥464
|
Glucagon, human
|
HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
|
≥95.0%
|
5mg
|
¥1,392
|
Epidermal Growth Factor Receptor Peptide (985-996)
|
DVVDADEYLIPQ
|
≥95.0%
|
1mg
|
¥180
|
Epidermal Growth Factor Receptor Peptide (985-996)
|
DVVDADEYLIPQ
|
≥95.0%
|
5mg
|
¥540
|
Brain Derived Acidic Fibroblast Growth Factor (1-11)
|
FNLPLGNYKKP
|
≥95.0%
|
1mg
|
¥165
|
Brain Derived Acidic Fibroblast Growth Factor (1-11)
|
FNLPLGNYKKP
|
≥95.0%
|
5mg
|
¥495
|
Brain Derived Basic Fibroblast Growth Factor (1-24)
|
PALPEDGGSGAFPPGHFKDPKRLY
|
≥95.0%
|
1mg
|
¥360
|
Brain Derived Basic Fibroblast Growth Factor (1-24)
|
PALPEDGGSGAFPPGHFKDPKRLY
|
≥95.0%
|
5mg
|
¥1,080
|
Brain Derived Acidic Fibroblast Growth Factor (102-111)
|
HAEKHWFVGL
|
≥95.0%
|
1mg
|
¥150
|
Brain Derived Acidic Fibroblast Growth Factor (102-111)
|
HAEKHWFVGL
|
≥95.0%
|
5mg
|
¥450
|
GTP-Binding Protein Fragment, Gs alpha
|
CKQLQKDKQVYRATHR
|
≥95.0%
|
1mg
|
¥240
|
GTP-Binding Protein Fragment, Gs alpha
|
CKQLQKDKQVYRATHR
|
≥95.0%
|
5mg
|
¥720
|
Histone H1-derived Peptide
|
GGGPATPKKAKKL
|
≥95.0%
|
1mg
|
¥165
|
Histone H1-derived Peptide
|
GGGPATPKKAKKL
|
≥95.0%
|
5mg
|
¥495
|
HIV-1 tat Protein (1-9)
|
MDPVDPNIE
|
≥95.0%
|
1mg
|
¥135
|
HIV-1 tat Protein (1-9)
|
MDPVDPNIE
|
≥95.0%
|
5mg
|
¥405
|
HIV-1 gag Protein p24 (194-210)
|
ANPDCKTILKALGPAAT
|
≥95.0%
|
1mg
|
¥255
|
HIV-1 gag Protein p24 (194-210)
|
ANPDCKTILKALGPAAT
|
≥95.0%
|
5mg
|
¥765
|
HIV-1 env Protein gp41 (1-23) amide (isolates BRU/JRCSF)
|
AVGIGALFLGFLGAAGSTMGARS-NH2
|
≥95.0%
|
1mg
|
¥378
|
HIV-1 env Protein gp41 (1-23) amide (isolates BRU/JRCSF)
|
AVGIGALFLGFLGAAGSTMGARS-NH2
|
≥95.0%
|
5mg
|
¥1,134
|
HIV (gp41) Fragment
|
AVGIGA
|
≥95.0%
|
1mg
|
¥120
|
HIV (gp41) Fragment
|
AVGIGA
|
≥95.0%
|
5mg
|
¥360
|
HIV (gp120) Fragment (318-327)
|
RGPGRAFVTI
|
≥95.0%
|
1mg
|
¥150
|
HIV (gp120) Fragment (318-327)
|
RGPGRAFVTI
|
≥95.0%
|
5mg
|
¥450
|
HIV-1 tat Protein (49-57)
|
RKKRRQRRR
|
≥95.0%
|
1mg
|
¥135
|
HIV-1 tat Protein (49-57)
|
RKKRRQRRR
|
≥95.0%
|
5mg
|
¥405
|
Laminin (925-933)
|
CDPGYIGSR
|
≥95.0%
|
1mg
|
¥135
|
Laminin (925-933)
|
CDPGYIGSR
|
≥95.0%
|
5mg
|
¥405
|
Laminin A Chain (2091-2108)
|
CSRARKQAASIKVAVSADR
|
≥95.0%
|
1mg
|
¥270
|
Laminin A Chain (2091-2108)
|
CSRARKQAASIKVAVSADR
|
≥95.0%
|
5mg
|
¥810
|
Laminin (929-933)
|
YIGSR
|
≥95.0%
|
1mg
|
¥75
|
Laminin (929-933)
|
YIGSR
|
≥95.0%
|
5mg
|
¥225
|
Laminin Penta Peptide, amide
|
YIGSR-NH2
|
≥95.0%
|
1mg
|
¥85
|
Laminin Penta Peptide, amide
|
YIGSR-NH2
|
≥95.0%
|
5mg
|
¥255
|
|
|
|
|
|
名稱
|
序列(一個字母)
|
純度
|
量
|
¥參考價
|
Leptin (93-105), human
|
NVIQISNDLENLR
|
≥95.0%
|
1mg
|
¥195
|
Leptin (93-105), human
|
NVIQISNDLENLR
|
≥95.0%
|
5mg
|
¥585
|
Leptin (116-130), mouse
|
SCSLPQTSGLQKPES
|
≥95.0%
|
1mg
|
¥225
|
Leptin (116-130), mouse
|
SCSLPQTSGLQKPES
|
≥95.0%
|
5mg
|
¥675
|
Leucokinin I
|
DPAFNSWG
|
≥95.0%
|
1mg
|
¥130
|
Leucokinin I
|
DPAFNSWG
|
≥95.0%
|
5mg
|
¥390
|
[DTrp6]-LH-RH, amide
|
Glp-HWSY-DTrp-LRPG-NH2
|
≥95.0%
|
1mg
|
¥210
|
[DTrp6]-LH-RH, amide
|
Glp-HWSY-DTrp-LRPG-NH2
|
≥95.0%
|
5mg
|
¥630
|
LH-RH, Free Acid
|
Glp-HWSYGLRPG
|
≥95.0%
|
1mg
|
¥165
|
LH-RH, Free Acid
|
Glp-HWSYGLRPG
|
≥95.0%
|
5mg
|
¥495
|
LH-RH, human, Gonadoreline
|
Glp-HWSYGLRPG-NH2
|
≥95.0%
|
1mg
|
¥175
|
LH-RH, human, Gonadoreline
|
Glp-HWSYGLRPG-NH2
|
≥95.0%
|
5mg
|
¥525
|
LH-RH, salmon
|
Glp-HWSYGWLPG-NH2
|
≥95.0%
|
1mg
|
¥175
|
LH-RH, salmon
|
Glp-HWSYGWLPG-NH2
|
≥95.0%
|
5mg
|
¥525
|
LH-RH, lamprey
|
Glp-HYSLEWKPG-NH2
|
≥95.0%
|
1mg
|
¥175
|
LH-RH, lamprey
|
Glp-HYSLEWKPG-NH2
|
≥95.0%
|
5mg
|
¥525
|
Mast Cell Degranulating Peptide HR-1
|
INLKAIAALVKKVL-NH2
|
≥95.0%
|
1mg
|
¥225
|
Mast Cell Degranulating Peptide HR-1
|
INLKAIAALVKKVL-NH2
|
≥95.0%
|
5mg
|
¥675
|
Mast Cell Degranulating Peptide HR-2
|
FLPLILGKLVKGLL-NH2
|
≥95.0%
|
1mg
|
¥225
|
Mast Cell Degranulating Peptide HR-2
|
FLPLILGKLVKGLL-NH2
|
≥95.0%
|
5mg
|
¥675
|
Melanocyte-Stimulating Hormone-Release Inhibiting Factor
|
PLG-NH2
|
≥95.0%
|
1mg
|
¥55
|
Melanocyte-Stimulating Hormone-Release Inhibiting Factor
|
PLG-NH2
|
≥95.0%
|
5mg
|
¥165
|
MAGE-3 Antigen (167-176), human
|
MEVDPIGHLY
|
≥95.0%
|
1mg
|
¥150
|
MAGE-3 Antigen (167-176), human
|
MEVDPIGHLY
|
≥95.0%
|
5mg
|
¥450
|
MAGE-3 Antigen (271-279), human
|
FLWGPRALV
|
≥95.0%
|
1mg
|
¥135
|
MAGE-3 Antigen (271-279), human
|
FLWGPRALV
|
≥95.0%
|
5mg
|
¥405
|
Mage-1 Antigen (161-169), human
|
EADPTGHSY
|
≥95.0%
|
1mg
|
¥135
|
Mage-1 Antigen (161-169), human
|
EADPTGHSY
|
≥95.0%
|
5mg
|
¥405
|
(Met 210) Melanoctye Protein PMEL 17 (209-217) (human)
|
IMDQVPFSV
|
≥95.0%
|
1mg
|
¥135
|
(Met 210) Melanoctye Protein PMEL 17 (209-217) (human)
|
IMDQVPFSV
|
≥95.0%
|
5mg
|
¥405
|
Ile-Thr-Asp-Gln-Val-Pro-Phe-Ser-Val
|
ITDQVPFSV
|
≥95.0%
|
1mg
|
¥135
|
Ile-Thr-Asp-Gln-Val-Pro-Phe-Ser-Val
|
ITDQVPFSV
|
≥95.0%
|
5mg
|
¥405
|
Trp-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp
|
WNRQLYPEWTEAQRLD
|
≥95.0%
|
1mg
|
¥240
|
Trp-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp
|
WNRQLYPEWTEAQRLD
|
≥95.0%
|
5mg
|
¥720
|
Systemin
|
AVQSKPPSKRDPPKMQTD
|
≥95.0%
|
1mg
|
¥270
|
Systemin
|
AVQSKPPSKRDPPKMQTD
|
≥95.0%
|
5mg
|
¥810
|
Flag Peptide
|
DYKDDDDK
|
≥95.0%
|
1mg
|
¥120
|
Flag Peptide
|
DYKDDDDK
|
≥95.0%
|
5mg
|
¥360
|
OVA 323-339
|
ISQAVHAAHAEINEAGR
|
≥95.0%
|
1mg
|
¥272
|
OVA 323-339
|
ISQAVHAAHAEINEAGR
|
≥95.0%
|
5mg
|
¥816
|
OVA peptide (257-264)
|
SIINFEKL
|
≥95.0%
|
1mg
|
¥120
|
OVA peptide (257-264)
|
SIINFEKL
|
≥95.0%
|
5mg
|
¥360
|
Myelin Basic Protein (68-84), guinea pig
|
YGSLPQKSQRSQDEN
|
≥95.0%
|
1mg
|
¥225
|
Myelin Basic Protein (68-84), guinea pig
|
YGSLPQKSQRSQDEN
|
≥95.0%
|
5mg
|
¥675
|
Hexa His
|
HHHHHH
|
≥95.0%
|
1mg
|
¥120
|
Hexa His
|
HHHHHH
|
≥95.0%
|
5mg
|
¥360
|
MOG 35-55
|
MEVGWYRSPFSRVVHLYRNGK
|
≥95.0%
|
1mg
|
¥336
|
MOG 35-55
|
MEVGWYRSPFSRVVHLYRNGK
|
≥95.0%
|
5mg
|
¥1,008
|
Motilin, canine
|
FVPIFTHSELQKIREKERNKGQ
|
≥95.0%
|
1mg
|
¥330
|
Motilin, canine
|
FVPIFTHSELQKIREKERNKGQ
|
≥95.0%
|
5mg
|
¥990
|
Motilin, human, porcine
|
FVPIFTYGELQRMQEKERNKGQ
|
≥95.0%
|
1mg
|
¥352
|
Motilin, human, porcine
|
FVPIFTYGELQRMQEKERNKGQ
|
≥95.0%
|
5mg
|
¥1,056
|
Myelin Basic Protein (87-99) (human, bovine, rat)
|
VHFFKNIVTPRTP
|
≥95.0%
|
1mg
|
¥195
|
Myelin Basic Protein (87-99) (human, bovine, rat)
|
VHFFKNIVTPRTP
|
≥95.0%
|
5mg
|
¥585
|
Neurokinin B
|
DMHDFFVGLM-NH2
|
≥95.0%
|
1mg
|
¥165
|
Neurokinin B
|
DMHDFFVGLM-NH2
|
≥95.0%
|
5mg
|
¥495
|
Neurokinin A / Substance K
|
HKTDSFVGLM-NH2
|
≥95.0%
|
1mg
|
¥160
|
Neurokinin A / Substance K
|
HKTDSFVGLM-NH2
|
≥95.0%
|
5mg
|
¥480
|
Neuromedin C
|
GNHWAVGHLM-NH2
|
≥95.0%
|
1mg
|
¥160
|
Neuromedin C
|
GNHWAVGHLM-NH2
|
≥95.0%
|
5mg
|
¥480
|
Neuromedin B
|
GNLWATGHFM-NH2
|
≥95.0%
|
1mg
|
¥160
|
Neuromedin B
|
GNLWATGHFM-NH2
|
≥95.0%
|
5mg
|
¥480
|
Neuromedin N
|
KIPYIL
|
≥95.0%
|
1mg
|
¥90
|
Neuromedin N
|
KIPYIL
|
≥95.0%
|
5mg
|
¥270
|
Neuromedin (U25), human
|
FRVDEEFQSPFASQSRGYFLFRPRN-NH2
|
≥95.0%
|
1mg
|
¥400
|
Neuromedin (U25), human
|
FRVDEEFQSPFASQSRGYFLFRPRN-NH2
|
≥95.0%
|
5mg
|
¥1,200
|
Neuropeptide Y, human
|
YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH2
|
≥95.0%
|
1mg
|
¥664
|
Neuropeptide Y, human
|
YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH2
|
≥95.0%
|
5mg
|
¥1,992
|
Neuropeptide Y (13-36), human
|
PAEDMARYYSALRHYINLITRQRY-NH2
|
≥95.0%
|
1mg
|
¥360
|
Neuropeptide Y (13-36), human
|
PAEDMARYYSALRHYINLITRQRY-NH2
|
≥95.0%
|
5mg
|
¥1,080
|
Neuropeptide K, porcine
|
DADSSIEKQVALLKALYGHGQISHKRHKTDSFVGLM-NH2
|
≥95.0%
|
1mg
|
¥598
|
Neuropeptide K, porcine
|
DADSSIEKQVALLKALYGHGQISHKRHKTDSFVGLM-NH2
|
≥95.0%
|
5mg
|
¥1,794
|
Kassinin
|
DVPKSDQFVGLM-NH2
|
≥95.0%
|
1mg
|
¥195
|
Kassinin
|
DVPKSDQFVGLM-NH2
|
≥95.0%
|
5mg
|
¥585
|
Nocistatin
|
EQKQLQ
|
≥95.0%
|
1mg
|
¥90
|
Nocistatin
|
EQKQLQ
|
≥95.0%
|
5mg
|
¥270
|
Mastoparan
|
INLKALAALAKKIL-NH2
|
≥95.0%
|
1mg
|
¥220
|
Mastoparan
|
INLKALAALAKKIL-NH2
|
≥95.0%
|
5mg
|
¥660
|
Mastoparan X
|
INWKGIAAMAKKLL-NH2
|
≥95.0%
|
1mg
|
¥220
|
Mastoparan X
|
INWKGIAAMAKKLL-NH2
|
≥95.0%
|
5mg
|
¥660
|
Neuropeptide FF
|
FLFQPQRF-NH2
|
≥95.0%
|
1mg
|
¥130
|
Neuropeptide FF
|
FLFQPQRF-NH2
|
≥95.0%
|
5mg
|
¥390
|
Diazepam-Binding Inhibitor Fragment, human
|
QATVGDINTERPGMLDFTGK
|
≥95.0%
|
1mg
|
¥320
|
Diazepam-Binding Inhibitor Fragment, human
|
QATVGDINTERPGMLDFTGK
|
≥95.0%
|
5mg
|
¥960
|
Men 10376
|
DY-DTrp-V-DTrp-DTrp-K-NH2
|
≥95.0%
|
1mg
|
¥205
|
Men 10376
|
DY-DTrp-V-DTrp-DTrp-K-NH2
|
≥95.0%
|
5mg
|
¥615
|
Physalaemin
|
Glp-ADPNKFYGLM-NH2
|
≥95.0%
|
1mg
|
¥205
|
Physalaemin
|
Glp-ADPNKFYGLM-NH2
|
≥95.0%
|
5mg
|
¥615
|
Phyllomedusin
|
Glp-NPNRFIGLM-NH2
|
≥95.0%
|
1mg
|
¥190
|
Phyllomedusin
|
Glp-NPNRFIGLM-NH2
|
≥95.0%
|
5mg
|
¥570
|
Corazonin
|
Glp-TFQYSRGWTN-NH2
|
≥95.0%
|
1mg
|
¥205
|
Corazonin
|
Glp-TFQYSRGWTN-NH2
|
≥95.0%
|
5mg
|
¥615
|
Neurotensin (8-13)
|
RRPYIL
|
≥95.0%
|
1mg
|
¥90
|
Neurotensin (8-13)
|
RRPYIL
|
≥95.0%
|
5mg
|
¥270
|
Obestatin (human)
|
FNAPFDVGIKLSGVQYQQHSQAL-NH2
|
≥95.0%
|
1mg
|
¥378
|
Obestatin (human)
|
FNAPFDVGIKLSGVQYQQHSQAL-NH2
|
≥95.0%
|
5mg
|
¥1,134
|
Nociceptin / Orphanin FQ
|
FGGFTGARKSARKLANQ
|
≥95.0%
|
1mg
|
¥254
|
Nociceptin / Orphanin FQ
|
FGGFTGARKSARKLANQ
|
≥95.0%
|
5mg
|
¥762
|
Orexin B, canine
|
RPGPPGLQGRLQRLLQASGNHAAGILTM-NH2
|
≥95.0%
|
1mg
|
¥458
|
Orexin B, canine
|
RPGPPGLQGRLQRLLQASGNHAAGILTM-NH2
|
≥95.0%
|
5mg
|
¥1,374
|
Orexin B, human
|
RSGPPGLQGRLQRLLQASGNHAAGILTM-NH2
|
≥95.0%
|
1mg
|
¥458
|
Orexin B, human
|
RSGPPGLQGRLQRLLQASGNHAAGILTM-NH2
|
≥95.0%
|
5mg
|
¥1,374
|
PACAP (1-38), human, ovine, rat
|
HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK-NH2
|
≥95.0%
|
1mg
|
¥684
|
PACAP (1-38), human, ovine, rat
|
HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK-NH2
|
≥95.0%
|
5mg
|
¥2,052
|
PACAP-Related Peptide (PRP), rat
|
DVAHEILNEAYRKVLDQLSARKYLQSMVA
|
≥95.0%
|
1mg
|
¥464
|
PACAP-Related Peptide (PRP), rat
|
DVAHEILNEAYRKVLDQLSARKYLQSMVA
|
≥95.0%
|
5mg
|
¥1,392
|
PACAP-Related Peptide (PRP), human
|
DVAHGILNEAYRKVLDQLSAGKHLQSLVA
|
≥95.0%
|
1mg
|
¥464
|
PACAP-Related Peptide (PRP), human
|
DVAHGILNEAYRKVLDQLSAGKHLQSLVA
|
≥95.0%
|
5mg
|
¥1,392
|
PACAP (1-27), human, ovine, rat
|
HSDGIFTDSYSRYRKQMAVKKYLAAVL-NH2
|
≥95.0%
|
1mg
|
¥442
|
PACAP (1-27), human, ovine, rat
|
HSDGIFTDSYSRYRKQMAVKKYLAAVL-NH2
|
≥95.0%
|
5mg
|
¥1,326
|
PACAP (6-27), human, ovine, rat
|
FTDSYSRYRKQMAVKKYLAAVL-NH2
|
≥95.0%
|
1mg
|
¥362
|
PACAP (6-27), human, ovine, rat
|
FTDSYSRYRKQMAVKKYLAAVL-NH2
|
≥95.0%
|
5mg
|
¥1,086
|
Chromostatin, bovine
|
SDEDSDGDRPQASPGLGPGP
|
≥95.0%
|
1mg
|
¥300
|
Chromostatin, bovine
|
SDEDSDGDRPQASPGLGPGP
|
≥95.0%
|
5mg
|
¥900
|
Pancreatic Polypeptide (rat)
|
APLEPMYPGDYATHEQRAQYETQLRRYINTLTRPRY-NH2
|
≥95.0%
|
1mg
|
¥684
|
Pancreatic Polypeptide (rat)
|
APLEPMYPGDYATHEQRAQYETQLRRYINTLTRPRY-NH2
|
≥95.0%
|
5mg
|
¥2,052
|
Pancreatic Polypeptide (human)
|
APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY-NH2
|
≥95.0%
|
1mg
|
¥684
|
Pancreatic Polypeptide (human)
|
APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY-NH2
|
≥95.0%
|
5mg
|
¥2,052
|
Insulin B (9 - 23)
|
SHLVEALYLVCGERG
|
≥95.0%
|
1mg
|
¥210
|
Insulin B (9 - 23)
|
SHLVEALYLVCGERG
|
≥95.0%
|
5mg
|
¥630
|
PAR - 1 Agonist;Protease - Activated Receptor - 1
|
TFLLRN
|
≥95.0%
|
1mg
|
¥90
|
PAR - 1 Agonist;Protease - Activated Receptor - 1
|
TFLLRN
|
≥95.0%
|
5mg
|
¥270
|
PAR-4 (1-6) amide (human)
|
GYPGQV-NH2
|
≥95.0%
|
1mg
|
¥100
|
PAR-4 (1-6) amide (human)
|
GYPGQV-NH2
|
≥95.0%
|
5mg
|
¥300
|
PAR-4 (1-6) (human)
|
GYPGQV
|
≥95.0%
|
1mg
|
¥90
|
PAR-4 (1-6) (human)
|
GYPGQV
|
≥95.0%
|
5mg
|
¥270
|
PAR-4 (1-6) amide (mouse)
|
GYPGKF-NH2
|
≥95.0%
|
1mg
|
¥100
|
PAR-4 (1-6) amide (mouse)
|
GYPGKF-NH2
|
≥95.0%
|
5mg
|
¥300
|
PAR-4 (1-6) (mouse)
|
GYPGKF
|
≥95.0%
|
1mg
|
¥90
|
PAR-4 (1-6) (mouse)
|
GYPGKF
|
≥95.0%
|
5mg
|
¥270
|
P34cdc2 Kinase Substrate Peptide
|
ADAQHATPPKKKRKVEDPKDF
|
≥95.0%
|
1mg
|
¥315
|
P34cdc2 Kinase Substrate Peptide
|
ADAQHATPPKKKRKVEDPKDF
|
≥95.0%
|
5mg
|
¥945
|
Tyrosinase (206-214), human
|
AFLPWHRLF
|
≥95.0%
|
1mg
|
¥136
|
Tyrosinase (206-214), human
|
AFLPWHRLF
|
≥95.0%
|
5mg
|
¥408
|
Substrate for Tyrosine Protein Kinase
|
RRLIEDNEYTARG
|
≥95.0%
|
1mg
|
¥194
|
Substrate for Tyrosine Protein Kinase
|
RRLIEDNEYTARG
|
≥95.0%
|
5mg
|
¥582
|
S6-1
|
RRLSSLRA
|
≥95.0%
|
1mg
|
¥122
|
S6-1
|
RRLSSLRA
|
≥95.0%
|
5mg
|
¥366
|
Phosphate Acceptor Peptide
|
RRKASGPPV
|
≥95.0%
|
1mg
|
¥136
|
Phosphate Acceptor Peptide
|
RRKASGPPV
|
≥95.0%
|
5mg
|
¥408
|
Malantide
|
RTKRSGSVYEPLKI
|
≥95.0%
|
1mg
|
¥210
|
Malantide
|
RTKRSGSVYEPLKI
|
≥95.0%
|
5mg
|
¥630
|
QKRPSQRSKYL
|
QKRPSQRSKYL
|
≥95.0%
|
1mg
|
¥150
|
QKRPSQRSKYL
|
QKRPSQRSKYL
|
≥95.0%
|
5mg
|
¥450
|
Protease-Activated Receptor-2, PAR-2 Agonist, amide
|
SLIGKV-NH2
|
≥95.0%
|
1mg
|
¥110
|
Protease-Activated Receptor-2, PAR-2 Agonist, amide
|
SLIGKV-NH2
|
≥95.0%
|
5mg
|
¥330
|
Melittin
|
GIGAVLKVLTTGLPALISWIKRKRQQ-NH2
|
≥95.0%
|
1mg
|
¥426
|
Melittin
|
GIGAVLKVLTTGLPALISWIKRKRQQ-NH2
|
≥95.0%
|
5mg
|
¥1,278
|
Kemptide
|
LRRASLG
|
≥95.0%
|
1mg
|
¥90
|
Kemptide
|
LRRASLG
|
≥95.0%
|
5mg
|
¥270
|
Phosphorylase Kinase b-Subunit (420-436)
|
KRNPGSQKRFPSNCGRD
|
≥95.0%
|
1mg
|
¥255
|
Phosphorylase Kinase b-Subunit (420-436)
|
KRNPGSQKRFPSNCGRD
|
≥95.0%
|
5mg
|
¥765
|
Myosin Kinase Inhibiting Peptide
|
KKRAARATS-NH2
|
≥95.0%
|
1mg
|
¥145
|
Myosin Kinase Inhibiting Peptide
|
KKRAARATS-NH2
|
≥95.0%
|
5mg
|
¥435
|
Syntide 2
|
PLARTLSVAGLPGKK
|
≥95.0%
|
1mg
|
¥225
|
Syntide 2
|
PLARTLSVAGLPGKK
|
≥95.0%
|
5mg
|
¥675
|
Tyrosinase (192-200), human mouse
|
SEIWRDIDF
|
≥95.0%
|
1mg
|
¥135
|
Tyrosinase (192-200), human mouse
|
SEIWRDIDF
|
≥95.0%
|
5mg
|
¥405
|
Tyr-Ile-Tyr-Gly-Ser-Phe-Lys
|
YIYGSFK
|
≥95.0%
|
1mg
|
¥105
|
Tyr-Ile-Tyr-Gly-Ser-Phe-Lys
|
YIYGSFK
|
≥95.0%
|
5mg
|
¥315
|
Casein Kinase II Substrate
|
RRREEETEEE
|
≥95.0%
|
1mg
|
¥210
|
Casein Kinase II Substrate
|
RRREEETEEE
|
≥95.0%
|
5mg
|
¥630
|
RREEETEEE
|
RREEETEEE
|
≥95.0%
|
1mg
|
¥189
|
RREEETEEE
|
RREEETEEE
|
≥95.0%
|
5mg
|
¥567
|
Ser25] Protein Kinase C (19-31)
|
RFARKGSLRQKNV
|
≥95.0%
|
1mg
|
¥195
|
Ser25] Protein Kinase C (19-31)
|
RFARKGSLRQKNV
|
≥95.0%
|
5mg
|
¥585
|
[Ala9] Autocamtide 2
|
KKALRRQEAVDAL
|
≥95.0%
|
1mg
|
¥195
|
[Ala9] Autocamtide 2
|
KKALRRQEAVDAL
|
≥95.0%
|
5mg
|
¥585
|
Autocamtide 2
|
KKALRRQETVDAL
|
≥95.0%
|
1mg
|
¥195
|
Autocamtide 2
|
KKALRRQETVDAL
|
≥95.0%
|
5mg
|
¥585
|
cAMP Dependent PK Inhibitor (5-22), amide
|
TTYADFIASGRTGRRNAI-NH2
|
≥95.0%
|
1mg
|
¥280
|
cAMP Dependent PK Inhibitor (5-22), amide
|
TTYADFIASGRTGRRNAI-NH2
|
≥95.0%
|
5mg
|
¥840
|
RR-SRC
|
RRLIEDAEYAARG
|
≥95.0%
|
1mg
|
¥195
|
RR-SRC
|
RRLIEDAEYAARG
|
≥95.0%
|
5mg
|
¥585
|
Protein Kinase C (19-35) Peptide
|
RFARKGALRQKNVHEVK
|
≥95.0%
|
1mg
|
¥255
|
Protein Kinase C (19-35) Peptide
|
RFARKGALRQKNVHEVK
|
≥95.0%
|
5mg
|
¥765
|
Protein Kinase C (gamma) Peptide
|
NYPLELYERVRTGC
|
≥95.0%
|
1mg
|
¥210
|
Protein Kinase C (gamma) Peptide
|
NYPLELYERVRTGC
|
≥95.0%
|
5mg
|
¥630
|
5FAM-RQMSFRL
|
5FAM-RQMSFRL
|
≥95.0%
|
1mg
|
¥276
|
5FAM-RQMSFRL
|
5FAM-RQMSFRL
|
≥95.0%
|
5mg
|
¥828
|
5FAM-RKRRQTSM
|
5FAM-RKRRQTSM
|
≥95.0%
|
1mg
|
¥294
|
5FAM-RKRRQTSM
|
5FAM-RKRRQTSM
|
≥95.0%
|
5mg
|
¥882
|
5FAM-RKRSRAEA-NH2
|
5FAM-RKRSRAEA-NH2
|
≥95.0%
|
1mg
|
¥304
|
5FAM-RKRSRAEA-NH2
|
5FAM-RKRSRAEA-NH2
|
≥95.0%
|
5mg
|
¥912
|
5FAM-RPRTSSF
|
5FAM-RPRTSSF
|
≥95.0%
|
1mg
|
¥276
|
5FAM-RPRTSSF
|
5FAM-RPRTSSF
|
≥95.0%
|
5mg
|
¥828
|
5FAM-RTKRSGSVYEPLKI-NH2
|
5FAM-RTKRSGSVYEPLKI-NH2
|
≥95.0%
|
1mg
|
¥420
|
5FAM-RTKRSGSVYEPLKI-NH2
|
5FAM-RTKRSGSVYEPLKI-NH2
|
≥95.0%
|
5mg
|
¥1,260
|
5FAM-NVKSKIGSTENLK-NH2
|
5FAM-NVKSKIGSTENLK-NH2
|
≥95.0%
|
1mg
|
¥402
|
5FAM-NVKSKIGSTENLK-NH2
|
5FAM-NVKSKIGSTENLK-NH2
|
≥95.0%
|
5mg
|
¥402
|
5FAM-DEEIYEELK-NH2
|
5FAM-DEEIYEELK-NH2
|
≥95.0%
|
1mg
|
¥322
|
5FAM-DEEIYEELK-NH2
|
5FAM-DEEIYEELK-NH2
|
≥95.0%
|
5mg
|
¥966
|
5FAM-QNPSRCSVSLSNVEA-NH2
|
5FAM-QNPSRCSVSLSNVEA-NH2
|
≥95.0%
|
1mg
|
¥438
|
5FAM-QNPSRCSVSLSNVEA-NH2
|
5FAM-QNPSRCSVSLSNVEA-NH2
|
≥95.0%
|
5mg
|
¥1,314
|
5FAM-ERRKSKSGA-NH2
|
5FAM-ERRKSKSGA-NH2
|
≥95.0%
|
1mg
|
¥312
|
5FAM-ERRKSKSGA-NH2
|
5FAM-ERRKSKSGA-NH2
|
≥95.0%
|
5mg
|
¥936
|
Hypercalcemia Malignancy Factor (1-34), human
|
AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTA
|
≥95.0%
|
1mg
|
¥578
|
Hypercalcemia Malignancy Factor (1-34), human
|
AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTA
|
≥95.0%
|
5mg
|
¥1,734
|
Hypercalcemia Malignancy Factor (1-34), amide, human
|
AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTA-NH2
|
≥95.0%
|
1mg
|
¥588
|
Hypercalcemia Malignancy Factor (1-34), amide, human
|
AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTA-NH2
|
≥95.0%
|
5mg
|
¥1,764
|
Parathyroid Hormone (1-34), rat
|
AVSEIQLMHNLGKHLASVERMQWLRKKLQDVHNF
|
≥95.0%
|
1mg
|
¥578
|
Parathyroid Hormone (1-34), rat
|
AVSEIQLMHNLGKHLASVERMQWLRKKLQDVHNF
|
≥95.0%
|
5mg
|
¥1,734
|
Parathyroid Hormone (1-34), bovine
|
AVSEIQFMHNLGKHLSSMERVEWLRKKLQDVHNF
|
≥95.0%
|
1mg
|
¥578
|
Parathyroid Hormone (1-34), bovine
|
AVSEIQFMHNLGKHLSSMERVEWLRKKLQDVHNF
|
≥95.0%
|
5mg
|
¥1,734
|
Angiotensinogen (1-14), human
|
DRVYIHPFHLVIHN
|
≥95.0%
|
1mg
|
¥210
|
Angiotensinogen (1-14), human
|
DRVYIHPFHLVIHN
|
≥95.0%
|
5mg
|
¥630
|
Acetyl Angiotensinogen (1-14), porcine
|
Ac-DRVYIHPFHLLVYS
|
≥95.0%
|
1mg
|
¥220
|
Acetyl Angiotensinogen (1-14), porcine
|
Ac-DRVYIHPFHLLVYS
|
≥95.0%
|
5mg
|
¥660
|
Acetyl, Angiotensinogen (1-14), human
|
Ac-DRVYIHPFHLVIHN
|
≥95.0%
|
1mg
|
¥220
|
Acetyl, Angiotensinogen (1-14), human
|
Ac-DRVYIHPFHLVIHN
|
≥95.0%
|
5mg
|
¥660
|
Renin Substrate Tetradecapeptide, rat
|
DRVYIHPFHLLYYS
|
≥95.0%
|
1mg
|
¥210
|
Renin Substrate Tetradecapeptide, rat
|
DRVYIHPFHLLYYS
|
≥95.0%
|
5mg
|
¥630
|
Angiotensinogen (1-14), porcine
|
DRVYIHPFHLLVYS
|
≥95.0%
|
1mg
|
¥210
|
Angiotensinogen (1-14), porcine
|
DRVYIHPFHLLVYS
|
≥95.0%
|
5mg
|
¥630
|
Angiotensinogen (1-13), human
|
DRVYIHPFHLVIH
|
≥95.0%
|
1mg
|
¥195
|
Angiotensinogen (1-13), human
|
DRVYIHPFHLVIH
|
≥95.0%
|
5mg
|
¥585
|
P-H-P-F-H-F-F-V-Y-K
|
PHPFHFFVYK
|
≥95.0%
|
1mg
|
¥150
|
P-H-P-F-H-F-F-V-Y-K
|
PHPFHFFVYK
|
≥95.0%
|
5mg
|
¥450
|
[Cys8] Renin Substrate Tetradecapeptide, rat
|
DRVYIHPCHLLYYS
|
≥95.0%
|
1mg
|
¥210
|
[Cys8] Renin Substrate Tetradecapeptide, rat
|
DRVYIHPCHLLYYS
|
≥95.0%
|
5mg
|
¥630
|
[Leu8] Renin Substrate Tetradecapeptide, rat
|
DRVYIHPLHLLYYS
|
≥95.0%
|
1mg
|
¥210
|
[Leu8] Renin Substrate Tetradecapeptide, rat
|
DRVYIHPLHLLYYS
|
≥95.0%
|
5mg
|
¥630
|
[Val8] Renin Substrate Tetradecapeptide, rat
|
DRVYIHPVHLLYYS
|
≥95.0%
|
1mg
|
¥210
|
[Val8] Renin Substrate Tetradecapeptide, rat
|
DRVYIHPVHLLYYS
|
≥95.0%
|
5mg
|
¥630
|
Secretin, rat
|
HSDGTFTSELSRLQDSARLQRLLQGLV-NH2
|
≥95.0%
|
1mg
|
¥417
|
Secretin, rat
|
HSDGTFTSELSRLQDSARLQRLLQGLV-NH2
|
≥95.0%
|
5mg
|
¥1,251
|
Secretin (5-27), porcine
|
TFTSELSRLRDSARLQRLLQGLV-NH2
|
≥95.0%
|
1mg
|
¥332
|
Secretin (5-27), porcine
|
TFTSELSRLRDSARLQRLLQGLV-NH2
|
≥95.0%
|
5mg
|
¥996
|
Secretin, human
|
HSDGTFTSELSRLREGARLQRLLQGLV-NH2
|
≥95.0%
|
1mg
|
¥442
|
Secretin, human
|
HSDGTFTSELSRLREGARLQRLLQGLV-NH2
|
≥95.0%
|
5mg
|
¥1,362
|
Selank
|
TKPRPGP
|
≥98.0%
|
1mg
|
¥108
|
Selank
|
TKPRPGP
|
≥98.0%
|
5mg
|
¥324
|
Somatostatin 28 (1-14)
|
SANSNPAMAPRERK
|
≥95.0%
|
1mg
|
¥210
|
Somatostatin 28 (1-14)
|
SANSNPAMAPRERK
|
≥95.0%
|
5mg
|
¥630
|
Somatostatin1-14
|
AGCKNFFWKTFTSC (C3&C14 bridge)
|
≥95.0%
|
1mg
|
¥320
|
Somatostatin1-14
|
AGCKNFFWKTFTSC (C3&C14 bridge)
|
≥95.0%
|
5mg
|
¥960
|
RC-160 (Vapreotide)
|
fCYwKVCW-NH2 (C2&C7 bridge)
|
≥95.0%
|
1mg
|
¥300
|
RC-160 (Vapreotide)
|
fCYwKVCW-NH2 (C2&C7 bridge)
|
≥95.0%
|
5mg
|
¥900
|
NTB (Naltriben)
|
DPhe-CY-DTrp-Orn-T-Pen-T-NH2(Cys2&Pen7 bridge)
|
≥95.0%
|
1mg
|
¥300
|
NTB (Naltriben)
|
DPhe-CY-DTrp-Orn-T-Pen-T-NH2(Cys2&Pen7 bridge)
|
≥95.0%
|
5mg
|
¥900
|
[DPro2,DPhe7,DTrp9] Substance P
|
R-DPro-KPQQ-DPhe-F-DTrp-LM-NH2
|
≥95.0%
|
1mg
|
¥265
|
[DPro2,DPhe7,DTrp9] Substance P
|
R-DPro-KPQQ-DPhe-F-DTrp-LM-NH2
|
≥95.0%
|
5mg
|
¥795
|
MG-132
|
RPKPQQFFGLM-NH2
|
≥95.0%
|
1mg
|
¥175
|
MG-132
|
RPKPQQFFGLM-NH2
|
≥95.0%
|
5mg
|
¥525
|
Pep-1
|
KETWWETWWTEWSQPKKKRKV
|
≥95.0%
|
1mg
|
¥336
|
Pep-1
|
KETWWETWWTEWSQPKKKRKV
|
≥95.0%
|
5mg
|
¥1,008
|
HIV-1 TAT Protein Peptide
|
YGRKKRRQRRR
|
≥95.0%
|
1mg
|
¥165
|
HIV-1 TAT Protein Peptide
|
YGRKKRRQRRR
|
≥95.0%
|
5mg
|
¥495
|
TAT 2-4
|
YGRKKRRQRRRGYGRKKRRQRRRG
|
≥95.0%
|
1mg
|
¥384
|
TAT 2-4
|
YGRKKRRQRRRGYGRKKRRQRRRG
|
≥95.0%
|
5mg
|
¥1,152
|
Scrambled TRAP Fragment
|
FSLLRN-NH2
|
≥95.0%
|
1mg
|
¥102
|
Scrambled TRAP Fragment
|
FSLLRN-NH2
|
≥95.0%
|
5mg
|
¥306
|
Hemoglobin (Hb) (64-76)
|
GKKVITAFNEGLK
|
≥95.0%
|
1mg
|
¥195
|
Hemoglobin (Hb) (64-76)
|
GKKVITAFNEGLK
|
≥95.0%
|
5mg
|
¥585
|
Thymopoietin II (32-34)
|
RKD
|
≥95.0%
|
1mg
|
¥60
|
Thymopoietin II (32-34)
|
RKD
|
≥95.0%
|
5mg
|
¥180
|
Thymopoietin II (32-35)
|
RKDV
|
≥95.0%
|
1mg
|
¥80
|
Thymopoietin II (32-35)
|
RKDV
|
≥95.0%
|
5mg
|
¥240
|
Thymopentin
|
RKDVY
|
≥95.0%
|
1mg
|
¥80
|
Thymopentin
|
RKDVY
|
≥95.0%
|
5mg
|
¥240
|
Urocortin II, human
|
IVLSLDVPIGLLQILLEQARARAAREQATTNARILARVGHC-NH2
|
≥95.0%
|
1mg
|
¥748
|
Urocortin II, human
|
IVLSLDVPIGLLQILLEQARARAAREQATTNARILARVGHC-NH2
|
≥95.0%
|
5mg
|
¥2,244
|
Urocortin III, mouse
|
FTLSLDVPTNIMNILFNIDKAKNLRAKAAANAQLMAQI-NH2
|
≥95.0%
|
1mg
|
¥694
|
Urocortin III, mouse
|
FTLSLDVPTNIMNILFNIDKAKNLRAKAAANAQLMAQI-NH2
|
≥95.0%
|
5mg
|
¥2,082
|
Urocortin III, human
|
FTLSLDVPTNIMNLLFNIAKAKNLRAQAAANAHLMAQI-NH2
|
≥95.0%
|
1mg
|
¥694
|
Urocortin III, human
|
FTLSLDVPTNIMNLLFNIAKAKNLRAQAAANAHLMAQI-NH2
|
≥95.0%
|
5mg
|
¥2,082
|
Urocortin, human
|
DNPSLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV-NH2
|
≥95.0%
|
1mg
|
¥735
|
Urocortin, human
|
DNPSLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV-NH2
|
≥95.0%
|
5mg
|
¥2,205
|
Urocortin, rat
|
DDPPLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV-NH2
|
≥95.0%
|
1mg
|
¥735
|
Urocortin, rat
|
DDPPLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV-NH2
|
≥95.0%
|
5mg
|
¥2,205
|
Urocortin III, mouse, free acid
|
FTLSLDVPTNIMNILFNIDKAKNLRAKAAANAQLMAQI
|
≥95.0%
|
1mg
|
¥684
|
Urocortin III, mouse, free acid
|
FTLSLDVPTNIMNILFNIDKAKNLRAKAAANAQLMAQI
|
≥95.0%
|
5mg
|
¥2,052
|
Urotensin I
|
NDDPPISIDLTFHLLRNMIEMARIENEREQAGLNRKYLDEV-NH2
|
≥95.0%
|
1mg
|
¥738
|
Urotensin I
|
NDDPPISIDLTFHLLRNMIEMARIENEREQAGLNRKYLDEV-NH2
|
≥95.0%
|
5mg
|
¥2,214
|
VIP, human, porcine, rat, ovine
|
HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2
|
≥95.0%
|
1mg
|
¥486
|
VIP, human, porcine, rat, ovine
|
HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2
|
≥95.0%
|
5mg
|
¥1,458
|
PHI, rat
|
HADGVFTSDYSRLLGQISAKKYLESLI-NH2
|
≥95.0%
|
1mg
|
¥469
|
PHI, rat
|
HADGVFTSDYSRLLGQISAKKYLESLI-NH2
|
≥95.0%
|
5mg
|
¥1,407
|
VIP, guinea pig
|
HSDALFTDTYTRLRKQMAMKKYLNSVLN-NH2
|
≥95.0%
|
1mg
|
¥458
|
VIP, guinea pig
|
HSDALFTDTYTRLRKQMAMKKYLNSVLN-NH2
|
≥95.0%
|
5mg
|
¥1,374
|
Peptide T
|
ASTTTNYT
|
≥95.0%
|
1mg
|
¥120
|
Peptide T
|
ASTTTNYT
|
≥95.0%
|
5mg
|
¥360
|
R15K, HIV-1 Inhibitory Peptide
|
RIQRGPGRAFVTIGK
|
≥95.0%
|
1mg
|
¥225
|
R15K, HIV-1 Inhibitory Peptide
|
RIQRGPGRAFVTIGK
|
≥95.0%
|
5mg
|
¥675
|